Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Active surveillance in intermediate-risk prostate cancer.

Klotz L.

BJU Int. 2019 Oct 24. doi: 10.1111/bju.14935. [Epub ahead of print] Review.

PMID:
31647166
2.

Active surveillance in intermediate risk prostate cancer.

Chandrasekar T, Herrera-Caceres JO, Klotz L.

Arch Esp Urol. 2019 Mar;72(2):157-166.

PMID:
30855017
3.

Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.

Alberts AR, Roobol MJ, Drost FH, van Leenders GJ, Bokhorst LP, Bangma CH, Schoots IG.

BJU Int. 2017 Oct;120(4):511-519. doi: 10.1111/bju.13836. Epub 2017 Apr 4.

4.

Evaluating localized prostate cancer and identifying candidates for focal therapy.

Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, Rubin MA, Scardino PT.

Urology. 2008 Dec;72(6 Suppl):S12-24. doi: 10.1016/j.urology.2008.10.004.

PMID:
19095124
5.

Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer.

Nassiri N, Margolis DJ, Natarajan S, Sharma DS, Huang J, Dorey FJ, Marks LS.

J Urol. 2017 Mar;197(3 Pt 1):632-639. doi: 10.1016/j.juro.2016.09.070. Epub 2016 Sep 14.

6.

Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.

Voss J, Pal R, Ahmed S, Hannah M, Jaulim A, Walton T.

BJU Int. 2018 Jun;121(6):863-870. doi: 10.1111/bju.14100. Epub 2018 Jan 17.

7.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.

8.

Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance.

Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P.

J Urol. 2019 Feb;201(2):292-299. doi: 10.1016/j.juro.2018.09.042.

PMID:
30240688
9.

Active surveillance and focal therapy for low-intermediate risk prostate cancer.

Klotz L.

Transl Androl Urol. 2015 Jun;4(3):342-54. doi: 10.3978/j.issn.2223-4683.2015.06.03. Review.

10.

National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?

Aghazadeh MA, Frankel J, Belanger M, McLaughlin T, Tortora J, Staff I, Wagner JR.

J Urol. 2018 May;199(5):1196-1201. doi: 10.1016/j.juro.2017.12.049. Epub 2017 Dec 26.

PMID:
29288120
11.

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.

Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1672-7. doi: 10.1111/j.1464-410X.2012.11434.x. Epub 2012 Aug 29.

12.

Active Surveillance for Prostate Cancer: How to Do It Right.

Garisto JD, Klotz L.

Oncology (Williston Park). 2017 May 15;31(5):333-40, 345. Review.

13.

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM.

BJU Int. 2012 Oct;110(8):1122-8. doi: 10.1111/j.1464-410X.2012.10986.x. Epub 2012 Feb 28.

14.

Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.

Musunuru HB, Yamamoto T, Klotz L, Ghanem G, Mamedov A, Sethukavalan P, Jethava V, Jain S, Zhang L, Vesprini D, Loblaw A.

J Urol. 2016 Dec;196(6):1651-1658. doi: 10.1016/j.juro.2016.06.102. Epub 2016 Aug 26.

PMID:
27569437
15.

An evidence review of active surveillance in men with localized prostate cancer.

Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J.

Evid Rep Technol Assess (Full Rep). 2011 Dec;(204):1-341. Review.

16.

Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.

KandaSwamy GV, Bennett A, Narahari K, Hughes O, Rees J, Kynaston H.

BJU Int. 2017 Nov;120(5B):E59-E63. doi: 10.1111/bju.13850. Epub 2017 Apr 19.

17.

Active surveillance for the management of prostate cancer in a contemporary cohort.

Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR.

Cancer. 2008 Jun 15;112(12):2664-70. doi: 10.1002/cncr.23502.

18.

Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.

Zumsteg ZS, Zelefsky MJ, Woo KM, Spratt DE, Kollmeier MA, McBride S, Pei X, Sandler HM, Zhang Z.

BJU Int. 2017 Nov;120(5B):E87-E95. doi: 10.1111/bju.13903. Epub 2017 Jun 3.

19.

Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.

van der Poel H, Klotz L, Andriole G, Azzouzi AR, Bjartell A, Cussenot O, Hamdy F, Graefen M, Palma P, Rivera AR, Stief CG.

World J Urol. 2015 Jul;33(7):907-16. doi: 10.1007/s00345-015-1603-7. Epub 2015 Jun 3.

PMID:
26037891
20.

Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.

Morlacco A, Cheville JC, Rangel LJ, Gearman DJ, Karnes RJ.

Eur Urol. 2017 Sep;72(3):442-447. doi: 10.1016/j.eururo.2016.08.043. Epub 2016 Aug 27.

PMID:
27574819

Supplemental Content

Support Center